Refocus Group, Inc. Stock

RFCS

US75865X2027

Biotechnology & Medical Research

OTC Markets Traded

Latest news: Refocus Group, Inc.

04/12/17	Refocus Group Submits Final Module for Pre-Market Approval of the VisAbility Micro Insert System for Presbyopia	CI
04/05/17	Refocus Group Concludes 12-Month Follow-Up for Phase 3 Clinical Trial on the Visability(Tm) Micro-Insert System for Presbyopia	CI
05/05/16	Refocus Group Inc. announced that it has received $15 million in funding from WP Global Partners, Inc., MedCare Investment Funds	CI
16/10/13	Refocus Group Inc. Announces Executive Changes	CI

More news

Managers and Directors: Refocus Group, Inc.

Manager	Title	Age	Since
J. Michael Judy CEO	Chief Executive Officer	-	28/10/2013
David Schanzlin CTO	Chief Tech/Sci/R&D Officer	-	01/02/2012
Selene A. Burke CTO	Chief Tech/Sci/R&D Officer	-	01/01/2006

Director	Title	Age	Since
Harry Jacobson BRD	Director/Board Member	78	01/01/2011
Thomas Loarie CHM	Chairman	-	02/01/2014
Thomas Lyles BRD	Director/Board Member	-	08/02/2010

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REFOCUS GROUP, INC.	-.--%	-99.99%	-	-	24
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	+1.20%	-2.30%	+21.39%	+80.93%	57.39B
LONZA GROUP AG	+1.91%	-1.37%	+3.41%	+37.22%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+748.97%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+31.45%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+111.69%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+54.06%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	+1.56%	+3.75%	+31.90%	+29.14%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-12.10%	24.34B
Average	+0.78%	-0.59%	+53.19%	+130.61%	43.39B
Weighted average by Cap.	+1.21%	-0.84%	+57.47%	+139.99%

See all sector performances

Refocus Group, Inc. is a medical device company. The Company is involved in researching and developing treatments for human vision disorders, particularly for the treatment of presbyopia. It is engaged in providing treatment for near vision correction. The Companyâ€™s product, VisAbility Micro Insert System, is a binocular presbyopic treatment that works outside the visual axis. VisAbility Micro Insert System is under clinical trials in the United States and aims to help patients reduce or eliminate their need for reading glasses.

Employees

Sector

Biotechnology & Medical Research

More about the company